2015-2025年,ASCO见证了中国创新药的崛起。2025年美国临床肿瘤学会(ASCO)年会近日举行,这是全球规模最大、最具权威性的临床肿瘤会议之一。今年的ASCO年会中,多家中国创新药企业最新在研成果入选,涉及PD-1双抗、ADC等领域,入选口头报告的中国研究者原创研究数量达70多项。正本溯源,中国创新药行业的起点是2015年药品审评审批制度改革,模仿FDA,CDE增加人员、缩短审评周期、...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.